Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia. What are the Challenges?

Hematology/Oncology Clinics of North America

Volumn 27, Issue 2, 2013, Pages 341-353

  Davila, Marco L ^a   Brentjens, Renier ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adoptive cell therapy; CD19; Cell engineering; Chimeric antigen receptor; Chronic lymphocytic leukemia

Indexed keywords

BENDAMUSTINE; CD19 ANTIGEN; CYCLOPHOSPHAMIDE; LYMPHOCYTE ANTIGEN RECEPTOR; PENTOSTATIN;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GENE THERAPY; CANCER PROGNOSIS; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG MEGADOSE; ELECTROPORATION; GAMMA IRRADIATION; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPOIESIS; MINIMAL RESIDUAL DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD19; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, ANTIGEN; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 84875778203     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.12.004     Document Type: Review

References (28)

1. Brentjens R.J., Latouche J.B., Santos E., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003, 9:279.
2. Brentjens R.J., Riviere I., Park J.H., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817.
3. Kalos M., Levine B.L., Porter D.L., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
4. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725.
5. Kochenderfer J.N., Dudley M.E., Feldman S.A., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011, 119(12):2709-2720.
6. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099.
7. Savoldo B., Ramos C.A., Liu E., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011, 121:1822.
8. Cooper L.J., Topp M.S., Serrano L.M., et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003, 101:1637.
9. Kowolik C.M., Topp M.S., Gonzalez S., et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006, 66:10995.
10. Brentjens R.J., Santos E., Nikhamin Y., et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007, 13:5426.
11. Brocker T., Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med 1995, 181:1653.
12. Milone M.C., Fish J.D., Carpenito C., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009, 17:1453.
13. Song D.G., Ye Q., Poussin M., et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012, 119:696.
14. Maher J., Brentjens R.J., Gunset G., et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002, 20:70.
15. Carpenito C., Milone M.C., Hassan R., et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009, 106:3360.
16. Zhong X.S., Matsushita M., Plotkin J., et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 2010, 18:413.
17. Fischer A., Abina S.H., Thrasher A., et al. LMO2 and gene therapy for severe combined immunodeficiency. N Engl J Med 2004, 350:2526.
18. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415.
19. Scholler J., Brady T.L., Binder-Scholl G., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012, 4:132ra53.
20. Jensen M.C., Popplewell L., Cooper L.J., et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010, 16:1245.
21. Till B.G., Jensen M.C., Wang J., et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012, 119:3940.
22. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269.
23. Dudley M.E., Yang J.C., Sherry R., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26:5233.
24. James S.E., Orgun N.N., Tedder T.F., et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood 2009, 114:5454.
25. Ho W.Y., Blattman J.N., Dossett M.L., et al. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003, 3:431.
26. Pegram H.J., Lee J.C., Hayman E.G., et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012, 119(18):4133-4141.
27. Kochenderfer J.N., Yu Z., Frasheri D., et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010, 116:3875.
28. Cheadle E.J., Hawkins R.E., Batha H., et al. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol 2010, 184:1885.